Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Inherited Cancer Registry (ICARE): Contribute to Research While Staying Informed
Inherited Cancer Registry (ICARE): Contribute to Research While Staying Informed

Inherited Cancer Registry (ICARE): Contribute to Research While Staying Informed

Clinicaltrials.gov identifier:
NCT03231891

Surveys, Registries, Interviews
People with an inherited mutation or cancer in the family

Study Contact Information:

Tuya Pal, MD, FACMG
Principal Investigator
Email: ICARE@vumc.org
Phone: 615-875-2444


Inherited Cancer Registry (ICARE): Contribute to Research While Staying Informed

About the Study

ICARE is a registry of individuals interested in participating in research, through which data and samples are collected to contribute to research. Participants are also provided with ongoing research and clinical updates and informed about other research opportunities for which they might be eligible. Participants are recruited across the United States and beyond. There is no cost to participate, and all materials can be completed online. To enroll into ICARE, please visit https://redcap.link/ICAREconsent.

What the Study Involves

Through ICARE, individuals interested in participating in studies focused on predisposition are recruited to a registry. Participants include individuals who carry a mutation (i.e., pathogenic or likely pathogenic variant) and/or () in an gene, as well as patients with an unexplained strong personal and/or family history of cancer. There is no cost to participate, and all materials can be completed online.

Participation involves completing an online consent, medical records and tissue/tumor release forms, as well as an initial and follow-up surveys. Saliva and/or tumor samples may also be requested from participants to conduct additional genomic analyses.

Additionally, participants are sent information about targeted research efforts for which they may be eligible. For example, we currently have various research efforts underway, including:

  1. A clinical trial to test online strategies to improve the delivery of follow-up care for those with gene mutations 
  2. A study among individuals with , , and mutations to evaluate breast cancer treatment and characteristics through conducting additional tumor genomic studies
  3. Additional tumor genomic studies in women with or mutations treated for breast cancer with Olaparib to evaluate whether this information could be used in the future to guide treatment

Lead Researcher

Tuya Pal, MD, FACMG
Principal Investigator
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center

This Study is Open To:

People who carry an inherited mutation in a gene linked to cancer, as well as patients with an unexplained strong personal and/or family history of cancer. 

This Study is Not Open To:

People under the age of 18.